COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:C43 - NL0011832936 - Common Stock
48.8 EUR
-1.2 (-2.4%)
Taking everything into account, C43 scores 8 out of 10 in our fundamental rating. C43 was compared to 53 industry peers in the Pharmaceuticals industry. C43 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: C43 is growing strongly while it also seems undervalued. Finally C43 also has an excellent dividend rating. These ratings would make C43 suitable for value and dividend and growth and quality investing!
1. Profitability
1.1 Basic Checks
C43 had positive earnings in the past year.
In the past year C43 had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: C43 reported negative net income in multiple years.
C43 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 20.60%, C43 belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
C43 has a Return On Equity of 26.74%. This is in the better half of the industry: C43 outperforms 76.92% of its industry peers.
The Return On Invested Capital of C43 (21.60%) is better than 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 49.94%, C43 belongs to the best of the industry, outperforming 98.08% of the companies in the same industry.
In the last couple of years the Profit Margin of C43 has grown nicely.
With an excellent Operating Margin value of 55.81%, C43 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of C43 has grown nicely.
Looking at the Gross Margin, with a value of 83.00%, C43 belongs to the top of the industry, outperforming 86.54% of the companies in the same industry.
In the last couple of years the Gross Margin of C43 has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
C43 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
C43 has less shares outstanding than it did 1 year ago.
C43 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, C43 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.80 indicates that C43 is not in any danger for bankruptcy at the moment.
The Altman-Z score of C43 (5.80) is better than 90.38% of its industry peers.
The Debt to FCF ratio of C43 is 0.01, which is an excellent value as it means it would take C43, only 0.01 years of fcf income to pay off all of its debts.
C43 has a better Debt to FCF ratio (0.01) than 98.08% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that C43 is not too dependend on debt financing.
C43's Debt to Equity ratio of 0.00 is amongst the best of the industry. C43 outperforms 94.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
A Current Ratio of 4.19 indicates that C43 has no problem at all paying its short term obligations.
With an excellent Current ratio value of 4.19, C43 belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
A Quick Ratio of 3.91 indicates that C43 has no problem at all paying its short term obligations.
C43's Quick ratio of 3.91 is amongst the best of the industry. C43 outperforms 96.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
C43 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1315.29%, which is quite impressive.
C43 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 85.20% yearly.
The Revenue has grown by 187.55% in the past year. This is a very strong growth!
The Revenue has been growing by 33.68% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
C43 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.02% yearly.
The Revenue is expected to grow by 22.67% on average over the next years. This is a very strong growth
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.98, the valuation of C43 can be described as very cheap.
C43's Price/Earnings ratio is rather cheap when compared to the industry. C43 is cheaper than 92.31% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.25, C43 is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.09, the valuation of C43 can be described as reasonable.
C43's Price/Forward Earnings ratio is rather cheap when compared to the industry. C43 is cheaper than 84.62% of the companies in the same industry.
C43's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.98.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, C43 is valued cheaper than 96.15% of the companies in the same industry.
C43's Price/Free Cash Flow ratio is rather cheap when compared to the industry. C43 is cheaper than 94.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
The excellent profitability rating of C43 may justify a higher PE ratio.
A cheap valuation may be justified as C43's earnings are expected to decrease with -27.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
C43 has a Yearly Dividend Yield of 3.85%. Purely for dividend investing, there may be better candidates out there.
In the last 3 months the price of C43 has falen by -28.24%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
C43's Dividend Yield is a higher than the industry average which is at 1.72.
Compared to an average S&P500 Dividend Yield of 1.92, C43 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
5.2 History
On average, the dividend of C43 grows each year by 7.41%, which is quite nice.
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
C43 pays out 24.09% of its income as dividend. This is a sustainable payout ratio.
The dividend of C43 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
FRA:C43 (4/29/2025, 7:00:00 PM)
48.8
-1.2 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Revenue(TTM)266.79M
Net Income(TTM)133.24M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 | ||
| P/S | 3.21 | ||
| P/FCF | 5.46 | ||
| P/OCF | 5.27 | ||
| P/B | 1.72 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 3.83 |
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROCE | 24.88% | ||
| ROIC | 21.6% | ||
| ROICexc | 28.38% | ||
| ROICexgc | 129.8% | ||
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% | ||
| FCFM | 58.76% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y181.33%
ROICexgc growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 46.02% | ||
| Cap/Sales | 2.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.77% | ||
| Profit Quality | 117.65% | ||
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.8 |
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What is the fundamental rating for C43 stock?
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.
What is the valuation status for C43 stock?
ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.
What is the profitability of C43 stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for C43 stock?
The Earnings per Share (EPS) of COSMO PHARMACEUTICALS NV (C43.DE) is expected to decline by -23.67% in the next year.
How sustainable is the dividend of COSMO PHARMACEUTICALS NV (C43.DE) stock?
The dividend rating of COSMO PHARMACEUTICALS NV (C43.DE) is 8 / 10 and the dividend payout ratio is 24.09%.